Manufacturers Life Insurance Company, The Lineage Cell Therapeutics, Inc. Transaction History
Manufacturers Life Insurance Company, The
- $102 Billion
- Q2 2024
A detailed history of Manufacturers Life Insurance Company, The transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 57,953 shares of LCTX stock, worth $52,737. This represents 0.0% of its overall portfolio holdings.
Number of Shares
57,953
Previous 58,383
0.74%
Holding current value
$52,737
Previous $86,000
33.72%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.3MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$37.9 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.71 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.53 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$4.28 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $154M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...